International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 2 , Pages 349-354 , 1 February 2010

Natural History of Clinically Staged Low- and Intermediate-Risk Prostate Cancer Treated With Monotherapeutic Permanent Interstitial Brachytherapy

  • Al V. Taira, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Washington, Seattle, WA
    • ,
  • Gregory S. Merrick, M.D.

      Affiliations

    • Schiffler Cancer Center and Wheeling Jesuit University, Wheeling, WV
    • Corresponding Author InformationReprint requests to: Gregory S. Merrick, M.D., Schiffler Cancer Center, Wheeling Hospital, 1 Medical Park, Wheeling, WV 26003. Tel: (304) 243-3490; Fax: (304) 243-5047
    • ,
  • Robert W. Galbreath, Ph.D.

      Affiliations

    • Schiffler Cancer Center and Wheeling Jesuit University, Wheeling, WV
    • ,
  • Kent E. Wallner, M.D.

      Affiliations

    • Puget Sound Healthcare Corporation, Group Health Cooperative, University of Washington, Seattle, WA
    • ,
  • Wayne M. Butler, Ph.D.

      Affiliations

    • Schiffler Cancer Center and Wheeling Jesuit University, Wheeling, WV

Received 21 November 2008 ,Revised 6 February 2009 ,Accepted 9 February 2009.

References 

  1. Bittner N, Merrick GS, Galbreath RW, et al. Primary causes of death after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2008;72:433–440
  2. Blasko JC, Grimm PD, Sylvester JE, et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:839–850
  3. Critz FA, Levinson K. 10-Year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. J Urol. 2004;172:2232–2238
  4. Grimm PD, Blasko JC, Sylvester JE, et al. 10-Year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31–40
  5. Kao J, Stone NN, Lavaf A, et al. (125)I monotherapy using D90 implant doses of 180 Gy or greater. Int J Radiat Oncol Biol Phys. 2008;70:96–101
  6. Sharkey J, Cantor A, Solc Z, et al. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: A 12-year experience from a single group practice. Brachytherapy. 2005;4:34–44
  7. Sylvester JE, Grimm PD, Blasko JC, et al. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys. 2007;67:57–64
  8. Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007;67:327–333
  9. Dattoli M, Wallner K, True L, et al. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer. 2007;110:551–555
  10. Merrick GS, Butler WM. Modified uniform seed loading for prostate brachytherapy: Rationale, design, and evaluation. Tech Urol. 2000;6:78–84
  11. Butler WM, Stewart RR, Merrick GS. A detailed radiobiological and dosimetric analysis of biochemical outcomes in a case control study of permanent prostate brachytherapy patients. Med Phys. In press.
  12. Nath R, Bice W, Butler WM, et al. AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer. Med Phys. In press.
  13. Stock RG, Stone NN, Cesaretti JA, et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys. 2006;64:527–533
  14. Kuban DA, Levy LB, Potters L, et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;65:1487–1493
  15. Nag S, Beyer D, Friedland J, et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999;44:789–799
  16. Stock RG, Stone NN, Dahlal M, et al. What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms. Brachytherapy. 2002;1:83–89
  17. Stock RG, Stone NN, Tabert A, et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998;41:101–108
  18. Stone NN, Stock RG, Unger P. Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer. J Urol. 2005;173:803–807
  19. Hernandez DJ, Nielsen ME, Han M, et al. Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. Urology. 2008;72:172–176
  20. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  21. Hull GW, Rabbani F, Abbas F, et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002;167:528–534
  22. Kupelian PA, Elshaikh M, Reddy CA, et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: A large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol. 2002;20:3376–3385
  23. Wallner K, Merrick G, Blasko JC, et al. Prostate brachytherapy made complicated. 3rd ed. Seattle: SmartMedicine Press; 2008;
  24. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet. 2002;360:103–106
  25. D'Amico AV, Manola J, Loffredo M, et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA. 2004;292:821–827
  26. Roach M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol. 2008;26:585–591
  27. Stone NN, Potters L, Davis BJ, et al. Customized dose prescription for permanent prostate brachytherapy: Insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys. 2007;69:1472–1477
  28. Stone NN, Potters L, Davis BJ, et al. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason Score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2009;73:341–346
  29. Merrick GS, Butler WM, Wallner KE, et al. Dosimetry of an extracapsular anulus following permanent prostate brachytherapy. Am J Clin Oncol. 2007;30:228–233
  30. Merrick GS, Butler WM, Wallner KE, et al. Extracapsular radiation dose distribution after permanent prostate brachytherapy. Am J Clin Oncol. 2003;26:e178–e189

 Conflict of interest: none.

PII: S0360-3016(09)00258-2

doi: 10.1016/j.ijrobp.2009.02.021

International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 2 , Pages 349-354 , 1 February 2010

Article Tools

* Image Usage & Resolution